Cornea Editor Julie Schallhorn, MD, shared the story of a personal friend of hers to introduce the “must-read” article on corneal side effects of cancer-specific therapies, also mentioning the articles on Sjogren’s disease and pinhole apertures in the management of irregular corneas.
The president and CEO of the Sjögren’s Foundation as well as two ophthalmologists spoke about the diagnosis journey, available treatments, and future hopes for patients with Sjögren’s disease.
Three glaucoma experts spoke to EyeWorld about pigment dispersion syndrome and pigmentary glaucoma, from diagnosis to treatment and monitoring, and what they want anterior segment surgeons who are not necessarily glaucoma specialists to know about it.
Chief Medical Editor Sumit “Sam” Garg, MD, spoke about his experience going “beyond the routine” with patients and previewed some of the articles in the issue. He also highlighted the importance of supporting ASCRS Government Relations.
The ASCRS Foundation offers several unique award and grant opportunities. Submission periods for the Chang-Crandall Humanitarian Award, the Young Eye Surgeons (YES) International Service Grant, and the Resident Excellence Awards are open now, with submission periods for Operation Sight Grants and the Volunteer of the Year Award opening at a later time.
In this YES Connect column, two surgeons described their techniques for how and when to successfully fixate a secondary lens when the capsule is either not present or not secure enough for traditional IOL implantation.
“Even with the wealth of new technologies available … refractive surprises, longer and shorter eyes, and unique medical histories persist. During these times we are called to flex our expertise and go beyond the routine to meet the needs of these patients,” said Karolinne Rocha, MD, introducing the articles in the Refractive section.
Antibody drug conjugates, an emerging area in cancer therapy, can pose a risk to the eye and cause adverse ocular events. Several experts discussed the research, what they’ve seen in terms of side effects, and considerations for patients taking these drugs and the eyecare providers monitoring them.
The DSLT laser (Voyager, Alcon) became commercially available in the U.S. earlier this year, and many surgeons are beginning to incorporate this into their glaucoma treatment paradigm. Several physicians discussed this new technology, how it compares to SLT, and how they’re using it in their practices.
As the commitment to sustainability in eyecare grows, the importance of educating the next generation of physicians is important. Medical students, residents, and fellows must be trained on best practices for waste reduction in the field. This column outlines the ongoing efforts to educate trainees in ophthalmology.